Dr. Fenske Discusses Ongoing Study In Frontline Mcl

Dr. Fenske Discusses Ongoing Study in Frontline MCL

Dr. Fenske Discusses Disease Progression on Ibrutinib in MCL

Dr. Fenske Discusses Targets Under Evaluation in MCL

Tycel Phillips, MD, on the Role of Targeted Therapies in Frontline MCL

Blood Cancers Today

Dr. Smith on Frontline Treatment Options in MCL

Dr. Fenske on the Utility of Next-Generation BTK Inhibitors in MCL

Dr Koff on Frontine and Maintenance Treatment Decision-Making in MCL

Dr. Fenske on the Future of Daratumumab in MCL

Dr. McKinney Discusses Ongoing Work in MCL

Dr. Leslie on the Current Frontline Treatment Landscape in MCL

Should we transplant or not in frontline therapy for MCL?

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Kahl Discusses the Potential of Frontline Ibrutinib in MCL

Dr. McKinney Discusses the Watch-and-Wait Approach in MCL

The HemOnc Pulse Live at ASH: Tycel Phillips, MD, on the TRIANGLE Study, Frontline Therapy in MCL

Blood Cancers Today

Dr. Cohen on the Potential of BTK Inhibitors in Frontline Treatment of MCL

Dr. Shah Discusses Autologous Transplant in MCL

Dr. Martin on the Frontline Treatment Landscape of MCL

Rebooting the BTK Inhibitor Sequence in MCL

PeerView Oncology

Dr. Wang on the Toxicity of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL

Dr. LaCasce Discusses the Future of MCL Treatment